Characterization of Factor VII From Transgenic Fish

转基因鱼中因子 VII 的表征

• 批准号: 6402973
• 负责人: SHARON D OGDEN
• 金额: $ 9.8万
• 依托单位: AQUAGENE, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6402973
• 关键词: biological products; bioreactors; biotechnology; carboxylation; coagulation factor VII; fish; gene targeting; genetically modified animals; glutamates; glycosylation; microinjections; protein biosynthesis; recombinant proteins

DESCRIPTION (provided by applicant): Organ specific expression of recombinant proteins in transgenic fish will be examined as an alternative to the production of complex proteins in tissue culture cells or the milk of large domestic animals. Fish have a high reproductive capacity, short breeding cycles, and embryos that are easy to manipulate. The fish bioreactor system will be appropriate for quick production of small quantities of protein for pre-clinical evaluation, and scale up to commercial production, at substantially lower costs than the current methods. Human coagulation Factor VII was chosen to test liver specific expression in fish. The recombinant protein will be purified and analyzed for specific activity, extent of gamma carboxylation of glutamic acid residues, and the degree of glycosylation. The expression level, purity and the cost per unit (or microgram) of the enzyme produced in fish can then be compared to those values for Factor VII products from other sources. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（由申请人提供）：重组体的器官特异性表达 转基因鱼中的蛋白质将被检查作为替代， 在组织培养细胞或大型哺乳动物的乳汁中生产复杂蛋白质 家畜鱼类有很高的繁殖能力，繁殖期短 周期和易于操作的胚胎。鱼类生物反应器系统 适合快速生产少量蛋白质， 临床前评估并扩大到商业生产，在 成本大大低于目前的方法。人凝血因子 选择VII来测试鱼中的肝脏特异性表达。重组 将纯化蛋白质并分析其比活性、γ-淀粉酶的程度、 谷氨酸残基的羧化和糖基化程度。的 表达水平、纯度和每单位（或微克）酶的成本 然后可以将鱼中产生的这些值与因子VII产品的值进行比较 从其他来源 拟议商业应用：不可用